---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-24-000079"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T12:17:16.374256+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zentalis reports FY2023 cash $483M, azenosertib ORR 37%, appoints CMO/CBO

## Summary
- Cash, equivalents and securities $482.9M at Dec 31, 2023; runway into 2026; plus $35M upfront from Immunome in Jan 2024.
- R&D expenses $189.6M (up 9.8%), G&A $64.4M (up 18%) versus FY2022.
- Azenosertib Phase 1 monotherapy showed 37% ORR and 6.5-month mPFS in platinum-resistant ovarian/USC cancer patients.
- Appointed Diana Hausman, M.D., as CMO and Kyle Rasbach, Ph.D., Pharm.D., as CBO.
- NDA submission for azenosertib in gynecologic malignancy targeted for 2026; multiple data readouts in 2024-2025.

## SEC filing metadata
- accession: 0001725160-24-000079
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000079/0001725160-24-000079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000079/zntl-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-24-000079
- JSON: https://secwatch.observer/filing/0001725160-24-000079.json
- Plain text: https://secwatch.observer/filing/0001725160-24-000079.txt

## Key facts
- Earnings Releases
  Zentalis Pharmaceuticals, Inc. reported financial results for the year ended December 31, 2023.
  - Period: the year ended December 31, 2023
  - Result: reported results
  source text: On February 27, 2024, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000079/0001725160-24-000079-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.